Strategic Acquisition ResoluteAI was acquired by Research Solutions in 2023, signaling a continuity of the AI-powered innovation workflow for scientific research. This creates a potential upsell path to integrated enterprise solutions or expanded analytics capabilities within the combined platform ecosystem.

Clinical Data Expansion Recent launch of Clinical Trials Analytics in 2023 indicates demand for connecting clinical trial data with publications and datasets. This presents a cross-sell opportunity to pharma, biotech, and CROs seeking end-to-end research and regulatory insights.

Lifecycle Solutions Product evolution from Nebula enterprise search to Collections and API enhancements shows a focus on collaboration, integration, and automation. Target teams that require scalable data discovery, reporting, and seamless third-party integrations.

Regulatory & Pharmacovigilance Active tools for post-market surveillance and pharmacovigilance suggest collaboration potential with medical affairs, regulatory, and safety groups in pharmaceutical companies that need real-time monitoring and signal detection across datasets.

SMB Growth Potential With a mid-market size and revenue in the lower range, ResoluteAI may be open to tiered pricing, managed services, or channel partnerships to accelerate adoption among mid-sized life sciences organizations prioritizing efficient, AI-powered research workflows.